Request an Annual Quote
The French biotech is raising Series A funds to support advancement of two preclinical candidates into clinical proof-of-concept.
Researchers combined tumor sequence, transcriptome, and patient immune cell response clues in their tumor-specific neoantigen detection and validation platform.
SB 273 will require health insurance plans to cover evidence-based biomarker tests for diagnosis, treatment, and management of a patient's disease.
The deal gives South Korea-based GC Cell the capability to manufacture its cytokine-induced killer therapy, Immuncell-LC, in North America.
The selection of the gene therapy candidate triggers a $5 million milestone payment from Neurocrine to Voyager in Q1.
The trial aims to gather evidence for the broad use of MRD testing across cancer types among some 1,200 patients.
The Phase I/II study will enroll infants and young children and run concurrently with trials testing the gene therapy in other age groups.
The company last year withdrew its BLA for the experimental stem cell therapy after an FDA advisory committee found the submitted data lacking.
The KOMET-008 trial of ziftomenib combinations will involve AML patients harboring either NPM1 mutations or KMT2A rearrangements.
CHMP recommended approval for tislelizumab monotherapy or in combination with chemo across three NSCLC indications.